Literature DB >> 16084156

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease.

Oscar C Marroquin1, Kevin E Kip, Suresh R Mulukutla, Paul M Ridker, Carl J Pepine, Tjendimin Tjandrawan, Sheryl F Kelsey, Sunil Mankad, William J Rogers, C Noel Bairey Merz, George Sopko, Barry L Sharaf, Steven E Reis.   

Abstract

BACKGROUND: Coronary artery microvascular dysfunction is prevalent in women with chest pain in the absence of obstructive coronary artery disease (CAD) and is manifested by attenuated coronary flow reserve (CFR). Markers of inflammation and endothelial cell activation have been found to be elevated in patients with chest pain but without CAD. The relationship between inflammation, endothelial activation, and CFR is not known.
METHODS: Ninety-four women with chest pain in the absence of obstructive angiographic CAD underwent catheterization-based assessment of CFR and measurement of levels of inflammatory markers (n = 78) and endothelial cell activation in the NHLBI WISE study.
RESULTS: Coronary flow reserve did not correlate with levels of C-reactive protein (high-sensitivity C-reactive protein) (rs = -0.07, P = .53), interleukin (IL)-6 (rs = -0.12, P = .31), IL-18 (rs = 0.14, P = .23), tumor necrosis factor alpha (rs = -0.09, P = .43), transforming growth factor beta1 (rs = 0.02, P = .84), and soluble intracellular adhesion molecule-1 (rs = 0.04, P = .68). Median levels of markers of inflammation and endothelial cell activation did not differ between the 57 women with abnormal CFR (< 2.5) and the 37 women with normal coronary microvascular function (high-sensitivity C-reactive protein 0.32 vs 0.25 mg/dL, P = .80; IL-6 2.89 vs 2.39 pg/mL, P = .63; IL-18 218 vs 227 pg/mL, P = .59; tumor necrosis factor alpha 2.7 vs 2.4 pg/mL, P = .43; transforming growth factor beta1 9928 vs 12436 pg/mL, P = .76; soluble intracellular adhesion molecule-1 286 vs 287 pg/mL, P = .95). Multivariable models demonstrated no evidence of associations between markers of inflammation and of endothelial cell activation and CFR.
CONCLUSIONS: Coronary microvascular dysfunction is not associated with markers of inflammation and endothelial cell activation in women with chest pain in the absence of obstructive CAD. These results suggest that inflammation and endothelial cell activation may not play a pathophysiological role in coronary microvascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084156     DOI: 10.1016/j.ahj.2004.08.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women.

Authors:  Megha Prasad; Eric L Matteson; Joerg Herrmann; Rajiv Gulati; Charanjit S Rihal; Lilach O Lerman; Amir Lerman
Journal:  Hypertension       Date:  2016-12-19       Impact factor: 10.190

Review 2.  Left ventricular diastolic dysfunction in women with nonobstructive ischemic heart disease: insights from magnetic resonance imaging and spectroscopy.

Authors:  Michael D Nelson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-08-09       Impact factor: 3.619

Review 3.  Gender and microvascular angina.

Authors:  Lynn Nugent; Puja K Mehta; C Noel Bairey Merz
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

4.  Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins.

Authors:  Viola Vaccarino; Durreshahwar Khan; John Votaw; Tracy Faber; Emir Veledar; Dean P Jones; Jack Goldberg; Paolo Raggi; Arshed A Quyyumi; J Douglas Bremner
Journal:  J Am Coll Cardiol       Date:  2011-03-15       Impact factor: 24.094

5.  Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment.

Authors:  Natale Daniele Brunetti; Roberto Padalino; Luisa De Gennaro; Andrea Cuculo; Luigi Ziccardi; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2008-08-09       Impact factor: 2.300

6.  Elevated renalase levels in patients with acute coronary microvascular dysfunction - A possible biomarker for ischemia.

Authors:  Basmah Safdar; Xiaojia Guo; Caitlin Johnson; Gail D'Onofrio; James Dziura; Albert J Sinusas; Jeffrey Testani; Veena Rao; Gary Desir
Journal:  Int J Cardiol       Date:  2019-01-02       Impact factor: 4.164

7.  Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential?

Authors:  Mark Slevin; Nessar Ahmed; Qiuyu Wang; Garry McDowell; Lina Badimon
Journal:  Vasc Cell       Date:  2012-04-30

8.  Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.

Authors:  Michael D Nelson; Behzad Sharif; Jaime L Shaw; Galen Cook-Wiens; Janet Wei; Chrisandra Shufelt; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Richard B Thompson; Eileen M Handberg; Carl J Pepine; Debiao Li; C Noel Bairey Merz
Journal:  Clin Cardiol       Date:  2016-12-22       Impact factor: 3.287

9.  Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia.

Authors:  Rajesh Mohandas; Mark S Segal; Tianyao Huo; Eileen M Handberg; John W Petersen; B Delia Johnson; George Sopko; C Noel Bairey Merz; Carl J Pepine
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

10.  Left ventricular circumferential strain and coronary microvascular dysfunction: A report from the Women's Ischemia Syndrome Evaluation Coronary Vascular Dysfunction (WISE-CVD) Project.

Authors:  Balaji Tamarappoo; T Jake Samuel; Omeed Elboudwarej; Louise E J Thomson; Haider Aldiwani; Janet Wei; Puja Mehta; Susan Cheng; Behzad Sharif; Ahmed AlBadri; Eileen M Handberg; John Petersen; Carl J Pepine; Michael D Nelson; C Noel Bairey Merz
Journal:  Int J Cardiol       Date:  2020-11-14       Impact factor: 4.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.